CTLA-4

Abstract arrangement of geometric shapes including spheres a pyramid and balancing wooden and stone slabs
Biotech

BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial

Analyst excitement about the efficacy data was offset by a challenging tolerability profile.
Nick Paul Taylor Dec 8, 2025 7:47am
Deal terminate tear up end deal scrap

UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data

Nov 6, 2025 10:00am
pipeline new drugs pipes faucet

Instil refills pipeline in $2B biobucks deal with ImmuneOnco

Aug 1, 2024 10:19am
cuts cut

BMS exits next-gen Yervoy pact, taking $300M in biobucks with it

Mar 12, 2024 7:07am
graphic image of stick figures being pushed out of a line indicating theyre being removed or fired

Agenus lays off 25%, sidelines programs to focus on cancer combo

Aug 23, 2023 11:04am
teeing up golf ball green

BioNTech's $200M bet on next-gen Yervoy triggers tumor responses

Jun 2, 2023 10:00am